Chronic lymphocytic leukemia (CLL) is the most common leukemia in the western world. The mechanism the mechanism of the disease development still remains unrevealed. In recent years new unique molecular and clinical features of CLL have emerged leading to a unified hypothesis of CLL origin. Major progress in understanding CLL biology was made after identification of mutational status of immunoglobulin variable heavy chain (IGHV) genes, which also improved prediction of patients' clinical outcome. Preferential usage of IGHV genes has led to recognition of CLL-specific B cell receptors (BCRs), called stereotyped BCRs. Taken together, these data point to antigen stimulation of CLL progenitor cells. Studies on CLL antibody reactivity have shown affinity to molecular motifs on apoptotic cells and bacterial cell structures, supporting the current hypothesis of the CLL pathomechanism. In this paper we have summarized information available to date regarding current theory of cellular origin and pathology of CLL.
IntroductIon
Chronic lymphocytic leukemia (CLL) is the most common leukemia in the western world and it represents about 25-30% of all leukemias. It affects mainly older people; the average age at the time of diagnosis is 65 years old [1, 21, 30, 32, 54] . In the course of CLL accumulation of B CD5
+ lymphocytes in peripheral blood, bone marrow, lymph nodes and spleen is observed [30, 32, 54] .
It is known that CLL is a very heterogeneous disease. Some patients demonstrate signs of rapid progression and need immediate therapy, while many cases experience a more favorable course and never require treatment [1] . Clinical heterogeneity of CLL is a reflection of genetic and epigenetic abnormalities as well as the microenvironmental influence involved in its pathogenesis, but the mechanism of the disease still remains unrevealed [32, 69] .
After the milestone discovery which was the mutational status of immunoglobulin variable heavy chain (IGHV) genes, immunoglobulin (Ig) genes became important prognostic markers allowing prediction of patient outcome. Comprehensive analysis of IGHV genes and definition of stereotyped B cell receptors (BCRs) have led to the most important theory of CLL pathogenesis known to date, namely the potential role of antigen (Ag) selection ( fig. 1 ). Studies on CLL antibody (Ab) reactivity have provided hints about the nature of recognized by malignant cells Ags and what the cell of origin is [55, 65] .
Cellular origin of CLL
Taking into account that CLL clones use mutated as well as unmutated IGHV genes, which divides patients into clinically distinct subgroups, a two-cell origin model can be considered. However, gene expression profiling (GEP) analysis shows a relatively small number of gene usage differences between unmutated CLL (U-CLL) and mutated CLL (M-CLL) in contrast to thousands of differences between healthy B lymphocytes [14] . The most distinctive phenotypic characteristic of CLL cells is expression of the CD5 molecule coupled with low levels of monoclonal surface immunoglobulins (sIg), usually class IgM or IgD; also the CD23 marker is present on leukemic cells. Although the precise origin of leukemic cells is still not clear, GEP and immunogenetic data suggest that CLL clones derive from competent B lymphocytes selected for clonal expansion and eventual transformation by multiple encounters and responses to antigens ( fig. 1 ). Therefore the unified parsimonious hypothesis that CLL is a malignancy of the mantle zone (MZ) subpopulation has been adopted [7, 26, 27, 55] .
The features of MZ cells could explain the origin of CLL cells. MZ B cells are defined as IgM
high IgD low , they can respond to bacterial polysaccharides in a T cell-independent manner, express either mutated or unmutated IGV genes, and the majority of human MZ B cells experience somatic hypermutations (SHM) [14, 27, 55] . The most significant feature of normal CD5 + B lymphocytes (B1) is an ability to produce polyreactive Ig that recognize variety of auto-antigens (autoAg) and cross-react with bacterial Ags. These natural auto-antibodies (autoAb) are encoded by the same group of IGV genes that are expressed in many cases of CLL. CLL cells and B1 cells also have in common other features, such as low expression of CD20 or myelomonocytic Ags -most frequently My4/CD14 [7, 14, 55] . [7, 14, 27] .
In contrast to current theory of cellular origin in CLL, recently published data have suggested that the disease initiating event may occur in hematopoietic stem cells. Apparently hematopoietic stem cells obtained from CLL patients and transplanted to xenograft models have a predisposition to generate clonal B cells with a CLL-like phenotype and certain IGHV genes usage [26, 41] .
Immunoglobulin genes in CLL
The discovery that somatic mutations of the Ig variable region genes occur in a subset of CLL patients and that the absence or presence of these mutations significantly correlates with clinical outcome was a milestone in understanding the biology of CLL [37, 62] . In general, patients with mutated IGHV genes follow a more indolent course compared to those with unmutated IGHV Fig. 1 [19] . The IGHV3-21 subgroup is very interesting as it has been proven that these genes are an exception from the prognostic classification of IGHV mutational status and were proposed as an independent adverse prognostic factor [19, 55, 65] . IGHV3-21 genes are usually expressed in M-CLL, although they can also be found in U-CLL. The whole subset of IGHV3-21, expressed by 11% of CLL patients, is associated with poor survival. Surprisingly, among M-CLL cases median survival is even shorter compared to U-CLL [11, 19, 29, 33, 37, 40, 44, 55, 65] . [4, 57] .
A number of studies have confirmed biased usage of the IGHV1-69 gene in CLL. Although over-usage of IGHV1-69 is observed also in other B cell proliferative disorders, it is important that IGHV1-69 is the most frequent gene over--represented in U-CLL patients [11, 65] . Several alleles of this gene has been found. They can be grouped into two types based on different sequences that encode the second complementarity-determining region (CDR2), but only 1 type of allele appears to be generally used in CLL -51p1 [40, 65] . Moreover, IGHV1-69 rearrangements are preferentially biased towards the usage of IGHD3-3, IGHD2-2 as well as IGHJ6 genes [37, 44, 65] . Another unusual molecular characteristic of IGHV1-69 rearrangements is a longer than average CDR3 sequence, which in that case have 19 codons [40, 65] . These features of IGHV1-69 over-usage are clearly different from those seen in B cells of the normal elderly population [65] . It has been reported that apart from IGHV1-69 also other genes from the IGHV1 family are over-used among U-CLL patients, namely:
The prognosis for patients with over-expression of the mentioned genes is poor [37] .
Another very frequent IGHV gene in CLL is IGHV4-34, usually over-expressed in M-CLL, although IGHV4-34 is also used at high frequency among healthy individuals [29, 33, 44, 65] . There are 2 different types of IGHV4-34 rearrangements reported: with short CDR3 associated with IGHJ4 gene usage and with a long CDR3 sequence coexisting with IGHJ6 over-expression [65] . Several scientific groups have established that more than 1% of CLL patients over-using IGHV4-34 with long CDR3 also over-express the IGKV2-30 gene [29, 33, 44] . In this sub- The authors employed the same criteria to assign patient sequences to subsets and reported an even higher proportion of patients belonging to different subsets. Almost 30% of sequences among the analyzed cohort were ascribed to one of 110 stereotyped subsets. The described study was focused on SHM patterns and based on the findings it has been concluded that among mutated subsets several of them showed distinctive mutations, which probably occurred due to the antigen response. These 'CLL-biased' and 'subset-biased' mutation patterns confirm the theory of antigen stimulation in the development of the IG gene repertoire in CLL and moreover show that beside CDR3 also other regions of V genes are involved in the antigen reaction ( fig. 1 ). [19, 24, 65] . In summary, all these data indicate that the IGHV3-21 subset represents an independent biological and possibly prognostic entity of CLL [24, 65] .
BCR stereotypy
The BCR is a multimeric complex formed by sIg non--covalently associated with heterodimer Igα/Igβ responsible for signal transduction (CD79a/CD79b) [7, 21, 61 [4, 9, 13, 44, 57, 61] .
Antigen stimulation
The above-described BCR stereotypy might suggest the role of superantigen in development of the disease ( fig.  1 ). In addition to asymmetric usage of IGHV genes, conserved sequences in HCDR3 point to selection of conventional antigen [62] . Monoclonal antibodies found in the circulation of malignant patients were defined as similar to natural IgM Abs with low affinity to microbes, lacking in SHM and with autoreactivity/polyreactivity. Enzyme immunoassay techniques provided further information. Auto-and polyreactivity are conversely associated with the mutational load of IG genes in BCRs [15, 37, 44, 51, 55] . Interestingly, it was observed that monoreactivity of several M-CLL mAbs can be converted to polyreactivity by reversal of the Ab amino acidic structure to that of the germline gene, suggesting that most CLL B cells derive from normal B lymphocytes with poly-or autoreactive BCRs [35, 37] . Chiorazzi's and Rosenquist's group have demonstrated that CLL mAbs could react with molecular motifs on apoptotic cells and bacteria [10, 12, 15, 51, 55] .
Ags reaction occurred in malignancy development and whether it was an incident taking place only once at a certain point of neoplastic transformation or it is an ongoing process. Sutton et al. [64] conducted an analysis of intraclonal diversification (ID) within IG genes through ongoing mutational activity. Results from ID study in other B-cell disorders point to ongoing SHM, proving that Ags constantly interact with neoplastic cells. The CLL ID data showed a little evidence for ongoing Ags stimulation in IgG and IgM B cells with the exception of subset #4, where all cells showed high levels of ID. These findings were confirmed by ID analysis of light chain genes in subset #4 cells. Therefore it seems likely that at least in particular subsets ongoing stimulation by Ags takes place after malignant transformation [46, 52, 55, 64] .
Autoimmune events in CLL
Patients with CLL might develop autoimmune disorders, primary directed against hematopoietic cells. Autoimmune complications probably appearing as a result of an impaired immune system frequently are severe and life--threatening for CLL patients and require medical intervention even when CLL is still quiescent and does not need specific therapy [8, 31, 34, 42, 53, 67] .
Autoimmune hemolytic anemia (AIHA) is strongly associated with CLL, as are immune thrombocytopenia (ITP) and rarely pure red cell aplasia (PRCA). The occurrence of immune cytopenias has been reported in many recent studies to range up to 25%. The most common disease is AIHA, while ITP and PRCA are more rare [22, 36] .
There are a few clinical and biological characteristics of CLL that have been associated with an increased risk of autoimmune cytopenia. It is known that advanced stage of CLL and age of patients correlate with more frequent occurrence of AIHA [3, 36] . AIHA and ITP have also been associated with poor prognostic factors, such as unmutated IGHV gene, high ZAP-70 expression and increased serum β2-microglobulin level [36] .
In the case of AIHA and ITP autoimmunity can be triggered by bystander non-malignant B cells or CLL cells. The etiology of anti-RBC Abs in CLL is not fully described yet, but several mechanisms have been proposed. Non--neoplastic B cells via T-cell mediated manner produce polyclonal high-affinity IgG that targets RhD, RhCcEe and B3 epitopes in AIHA and GpIIIb/IIIa in case of ITP. Then opsonized cells are destroyed via antibody-dependent cellular cytotoxicity. It is unknown which normal cells are involved in this process, but significant increases of CD4 + T cells and NK cells in peripheral blood have been observed [22, 63] . It has also been suggested that autoreactive T helper cells occurrence might be induced by autoAgs directly presented by CLL cells. In that case tumor necrosis factors, such as B-cell activator factor (BAFF) and proliferation-inducing ligand (APRIL), probably play an important role [22, 36, 63] .
with autoAgs of cytoplasmic and perinuclear origin [25, 28, 39, 43, 44, 48, 49, 58] . Interestingly, all of these proteins have a functional connection with microbial infections and/or apoptotic cell eradication [55] . Nonmuscle myosin heavy chain IIA (MYHIIA) is an important protein in eukaryotic cells that plays a role in several cellular processes, including cell motion. Chu et al. [17, 18] published two separate papers in Blood on the subject of MYHIIA. They established that MYHIIA is targeted by stereotyped mAbs from subset #6 with IGHV1-69/IGHD3-16/IGHJ3 rearrangements (table 1) . This 225 kDa protein is cleaved by caspases and rearranges in the cytoplasm, transferring to the surface of the cell during apoptosis, then recognition of MYHIIA by CLL mAbs becomes possible. Such MYHIIA-exposed apoptotic cells were defined as MEACs. Interestingly, MEAC binding was observed among U-CLL patients and high reactivity correlated with poor survival. Data obtained by Chu et al. [17, 18] indicate that MEAC reactivity might determine CLL clone behavior [39, 44, 55, 58] .
Vimentin, a type III cytoskeletal protein, was found to function on the external side of the plasma membrane and to be secreted after bacterial infection. This protein not only maintains the architecture of cells, but also participates in transcellular migration, cell adhesion, cellular signaling and wound healing. Vimentin in a stress response can be exhibited on apoptotic primary T cells, neutrophils, platelets and oxLDL-binding macrophages [28, 49, 51, 55] . Myhrinder et al. [51] found that subset #32 mAbs with IGHV3-30.3UM as well as mAbs with mutated IGHV3-30 gene rearrangements react with vimentin (table 1) [51] .
Filamin was the first discovered non-muscle actin binding protein. There are three isoforms of this protein: filamin A, B and C [25] . Isoforms A and B are cross linking proteins participating in over forty molecular interactions, both being exposed on the surface of apoptotic cells. Unmutated HG3/IGHV1-2 mAbs were established to bind filamin B as well as oxLDL Ags and apoptotic Jurkat cells (table 1) [25, 51, 55] .
Cofilin-1 is another cytoskeletal protein that possibly plays a role in CLL pathogenesis. Cofilin-1 is a member of the actin binding and depolarizing family and it has been identified in a wide range of eukaryotic organisms. In an unphosphorylated form this protein has the ability to bind both globular and filamentous actin, promoting their dynamics for motility, development, polarity as well as cytokinesis [66, 68] . In final stages of apoptosis cofilin-1 is exposed in apoptotic blebs. When oxidation of the protein is inhibited, oxidant-induced apoptosis is stopped [43, 48, 51] . Cofilin-1 was discovered to be targeted by three leukemic mAbs: unmutated Igs belonging to subset #5 CII/IGHV1-69, mutated 232B4/IGHV3-48 and subset #2 mAbs rIGHV3-21M (table 1) [51, 55] .
Despite strong evidence supporting the role of Ags stimulation in CLL ontogeny, it is still not clear when the between neoplastic cells, pathologically functioning T cells, the microenvironment and the immune system. Occurrence of autoimmune disorders in CLL is not fully understood yet, but autoreactivity against formed elements of blood appears to be related to the ability of malignant cells to process and present Ags derived from blood cells [3, 36] .
Alternative approach to CLL pathomechanism
Recently Duhren-von Minden et al. [23] presented a novel theory for CLL development. According to their data, CLL is driven by antigen-independent, cell-autonoIn the case of PRCA in CLL the mechanism is not well defined, but it appears to be humorally mediated [22] .
Non-hematological autoimmune events in CLL are rare. To date in numerous reports cases of rheumatoid arthritis, systemic lupus erythematosus, ulcerative colitis, pernicious anemia, Sjogren's syndrome, Grave's disease, nephritic syndrome, pemphigus, glomerulosclerosis and paraneoplastic neurological syndrome have been described [34, 53] .
The process underlying development of autoimmune disorders in CLL is complex. It requires interactions 
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S. pneumoniae, S. pyogenes, E. faecium, E. faecalis, E. cloacae
44, 45, 60 Although new facts in regard of CLL biology and cell origin are continuously emerging, the primary cause of leukemia still needs to be investigated for better understanding of CLL etiology.
mous signaling. Apparently HCDR3 interacts with intrinsic motifs, such as a sequence in the second framework region (FR2), within the same or nearby BCRs, consequently inducing cell-autonomous signaling independent of extrinsic epitopes. Moreover, HCDR3 sequences derived from leukemic BCRs are able to transfer autonomous signaling capacity to other BCRs. Irrespectively of IGHV mutational status and BCR stereotypy, in all CLL sIgs autonomous signaling was observed [13, 23] . In Cell Research Chiorazzi and Efremov commented on this newly discovered signaling as Ag-dependent. According to the authors, the described interaction of HCDR3 with epitopes can be considered as an example of autoreactivity, where selection of B cells with HCDR3 sequences recognizing FR2 autoepitopes takes place [13] . Therefore the newly discovered interaction of HCDR3 sequences with the FR2 region may be a confirmation of the current antigen-driven CLL development hypothesis.
conclusIons
Aforementioned evidence indicates the importance of Ag stimulation in the leukemogenesis of CLL. Analysis
